Mode
Text Size
Log in / Sign up
Phase 4 Completed N=93 Randomized Triple-blind Treatment

Parasternal Nerve Block Using Bupivacaine for Postoperative Analgesia in Children Undergoing Cardiac Surgery

Source: ClinicalTrials.gov NCT02512861 ↗
Enrolled (actual)
93
Serious AEs
11.5%
Results posted
Aug 2018
Primary outcomePrimary: Total Fentanyl/Equivalent Day 0-1 — 23.6; 22.4 mcg/kg/day
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

All pediatric patients who undergo cardiac surgery require analgesic medications for postoperative pain control and many require sedation to facilitate comfort with cares. Parasternal infiltration of local anesthetic for nerve blocks is a simple option to postoperative analgesia. The investigators hypothesize that Bupivacaine, a parasternal nerve block administered in pediatric patients undergoing cardiac surgery will reduce the requirement of Opioids and other pain medications as well as decrease postoperative pain scores. This is a prospective, double-blind, randomized controlled trial. Subjects are randomized to receive either 0.25% Bupivacaine or normal saline following their cardiothoracic surgery.

Outcome Measures

OutcomeResultp-value
PRIMARY
Total Fentanyl/Equivalent Day 0-1
23.6; 22.4
PRIMARY
Patient-Controlled Analgesia (PCA) Fentanyl/Equivalent Day 0-1
15.7; 14.6
SECONDARY
Postoperative Length of Intubation
5.9; 6.4
SECONDARY
Postoperative Cortisol Levels
9.4; 9.1
SECONDARY
Postoperative Pain Scores-Face, Legs, Activity, Cry, Consolability (FLACC) Scale
0; 0
SECONDARY
Postoperative Pain Scores-State Behavioral Scale (SBS)
-0.25; -0.25

Eligibility Criteria

Inclusion Criteria

  • Age 0-17 years old at time of surgery
  • Society of Thoracic Surgeons- European Association for Cardio-Thoracic Surgery (STAT) mortality categories 1-3
  • Surgical intervention requiring median sternotomy
  • Expected extubation within 24 hours of surgery

Exclusion Criteria

  • Known allergic reaction or hypersensitivity to Bupivacaine or to any local anesthetic agent of the amide type
  • Delayed sternum closure
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02512861). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search